Insights

The business development playbook at most contract development and manufacturing organizations (CDMOs) and formulation vendors follows a predictable arc: attend […]

There is a moment inside every biopharma brand team, usually around 36 months before patent expiration, when the commercial organization

Every quarter, brand-name pharmaceutical manufacturers risk losing billions in revenue because a generic competitor files an Abbreviated New Drug Application

There is a moment in every branded drug’s commercial life when a payer’s finance team opens a spreadsheet and starts

Every year, branded pharmaceutical manufacturers watch billions of dollars in revenue evaporate within months of a patent expiry. Generic filers

Patent cliffs kill revenue. Investors know it. What they often lack is a precise, well-sourced, actionable briefing that tells them

The global pharmaceutical industry is entering a period of wealth transfer that has no historical equivalent. Between 2025 and 2030,

The $2 Billion Filing Error In March 2000, the USPTO denied a patent term extension application filed by Pfizer for

The Name Behind the Molecule Every drug in clinical use has at least three names. There is the brand name,